重组因子IX融合蛋白的特征,使其能够进行皮下注射
Kathrin Schön1, Sabine Pestel2, Julia Riedesel2
1Pharmacology & Toxicology, Research, CSL Innovation GmbH, Marburg, Hesse, Germany; Institute of Pharmacology, Biochemical-Pharmacological Center, University of Marburg, Marburg, Hesse, Germany.
Journal of thrombosis and haemostasis : JTH
|July 17, 2024
概括
这项研究开发了一种新型重组因子IX-FP (rIX-FP) 变体R338L,该变体在B型血友病治疗中显示出增强的特异性活性和疗效. 这种R338L变种在皮下注射方面表现有前途,可能为患者简化治疗.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病B是一种X系出血疾病,由因子IX (FIX) 基因突变引起,需要终身替代疗法.
- 目前的复合FIX-FP (rIX-FP) 疗法提供更长的半衰期,但仍然需要复杂的静脉注射 (IV). 管理. 管理.
研究的目的:
- 对于潜在的皮下 (s.c.) 给药,具有增强特异性活性的rIX-FP变体的特征.
- 在临床前模型中评估这些变体的药理动力学和疗效概况.
主要方法:
- 在体外对两种rIX-FP变体 (R338L和R338L/E410K) 的特异性表征.
- 在IV治疗后,在FIX缺乏的小鼠中进行的药理动力学评估. 和SC的管理.
- 在尾部剪切出血模型中进行有效性测试,将变体与野生型rIX-FP.比较.
主要成果:
- 与野生型rIX-FP相比,这两种变种的特异活性增加了4到5倍.
- 在R338L变种中,在输液和输液后,FIX活动暴露率更高. 和SC的管理.
- 在小鼠中,R338L变体的疗效与野生类型的rIX-FP相当,但需要的蛋白质约为四倍.
结论:
- 这种rIX(R338L) -FP变体是皮下血友病B治疗的有希望的候选者.
- 其增加的特异活性和增加的暴露支持降低剂量和简化管理的潜力.
相关概念视频
01:25Routes of Drug Administration: Parenteral
1.9K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
1.9K
01:29Drug Delivery: Parenteral Route
470
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
470